Table 2.
Clinical characteristics stratified by MCV tertiles.
| Variable | Mean corpuscular volume, fl | |||
|---|---|---|---|---|
| MCV-L (64.6-91.0) N = 146 | MCV-M (91.1-95.3) N = 145 | MCV-H (95.4-113.3) N = 146 | P value | |
| Mean corpuscular volume, fl | 88.6 (86.5-90.25) | 93.30 (91.90-94.20) | 98.00 (96.30-100.55) | <0.001 |
| Age, year | 59.24 ± 10.6 | 60.43 ± 9.7 | 61.36 ± 10.4 | 0.210 |
| Sex | ||||
| Male, % | 105 (74.0) | 115 (79.3) | 120 (80.1) | 0.183 |
| Body mass index, kg/m2 | 25.59 ± 3.09 | 24.78 ± 3.36 | 24.66 ± 3.26 | 0.064 |
| Smoking, % | 85 (58.2) | 71 (49.0) | 90 (65.8) | 0.079 |
| Past MI, % | 23 (15.8) | 23 (15.9) | 22 (15.1) | 0.980 |
| Past PCI or CABG, % | 31 (21.2) | 30 (20.7) | 25 (17.1) | 0.631 |
| Hypertension, % | 84 (57.5) | 75 (51.7) | 69 (47.3) | 0.212 |
| Diabetes, % | 67 (45.9) | 47 (32.4) | 29 (19.9) | <0.001 |
| Family history, % | 59 (40.4) | 52 (35.9) | 65 (44.5) | 0.322 |
| Diastolic blood pressure, mmHg | 80 (70-90) | 80 (70-85) | 80 (70-86) | 0.154 |
| Systolic blood pressure, mmHg | 120 (118-140) | 120 (110-140) | 125 (114-140) | 0.811 |
| Heart rate, bmp | 70 (62-76) | 69 (61-77) | 67 (61-78) | 0.764 |
| Hemoglobin A1c, % | 6.15 (5.70-7.65) | 6.05 (5.62-6.50) | 5.80 (5.50-6.20) | <0.001 |
| Left ventricle ejection fraction, % | 62 (48-69) | 62 (47-68) | 61 (49-68) | 0.873 |
| Hemoglobin, g/L | 139.00 (125.50-150.50) | 140.00 (130.00-152.00) | 141.00 (127.00-151.00) | 0.846 |
| Platelet, 103 cells/dL | 186.00 (155.50-219.00) | 181.00 (143.75-218.00) | 172.00 (137.00-214.00) | 0.230 |
| Creatinine, mg/dL | 66.43 (57.35-76.69) | 66.32 (57.26-75.33) | 78.81 (60.05-79.60) | 0.174 |
| Triglycerides, mmol/L | 1.49 (1.11-2.06) | 1.41 (1.09-1.96) | 1.41 (0.98-1.80) | 0.887 |
| High-density lipoprotein, mmol/L | 0.87 (0.77-1.03) | 0.89 (0.76-1.28) | 0.87 (0.74-1.07) | 0.670 |
| Low-density lipoprotein, mmol/L | 2.14 (1.67-2.73) | 2.19 (1.74-2.63) | 2.02 (1.46-2.73) | 0.336 |
| High-sensitivity C-reactive protein, mg/L | 1.53 (0.74-3.63) | 1.16 (0.69-3.00) | 1.38 (0.74-3.78) | 0.423 |
| Creatine kinase isoenzymes MB, U/L | 14.20 (10.91-26.50) | 16.85 (12.20-35.03) | 16.75 (12.24-37.96) | 0.068 |
| Pro-B-type natriuretic peptide, pg/ML | 368.90 (116.60-886.30) | 403.80 (171.50-1005.00) | 335.20 (121.4-1160.00) | 0.724 |
| Major adverse cardiovascular events, % | 42 (28.8) | 37 (25.5) | 61 (41.8) | 0.007 |
| Type of acute coronary syndrome, % | 0.781 | |||
| Unstable angina | 86 (58.9) | 76 (52.4) | 78 (53.4) | |
| ST-segment elevation myocardial infarction | 40 (27.4) | 46 (31.7) | 48 (32.9) | |
| Non-ST-segment elevation myocardial infarction | 20 (13.7) | 23 (15.9) | 20 (13.7) | |
| Lesion vessel number, % | 0.083 | |||
| 1 | 15 (10.3) | 27 (18.6) | 26 (17.8) | |
| 2 | 43 (29.5) | 48 (33.1) | 35 (24.0) | |
| 3 | 88 (60.3) | 70 (48.3) | 85 (58.2) | |
| Medicine at discharge, % | ||||
| Aspirin | 146 (100) | 145 (100) | 142 (97.3) | a |
| Clopidogrel | 140 (95.9) | 143 (98.6) | 142 (97.3) | 0.404 |
| ACEI/ARB | 133 (91.1) | 134 (92.4) | 131 (89.7) | 0.724 |
| Calcium channel blockers | 40 (27.4) | 24 (16.4) | 31 (21.2) | 0.080 |
| β-Blockers | 125 (85.6) | 126 (86.9) | 134 (91.8) | 0.230 |
| Statin | 143 (97.9) | 143 (98.6) | 143 (97.9) | a |
Data are presented as mean ± SD, median (IQR) or number (%); “a” represents P value =1. MCV: mean corpuscular volume; MI: myocardial infarction; PCI or CABG: past percutaneous coronary intervention or coronary artery bypass grafting; ACEI: angiotensin-converting enzyme inhibition; ARB: angiotensin receptor blocker.